Acabrunat 100mg Capsule

Acabrunat 100mg capsule is an anti-cancer medication used in the treatment of treat mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL) and other disorders involving abnormal white blood cells that are the part of immune system. The medicine’s active ingredient is Acalabrutinib in the form of 100mg and belongs to the therapeutic class of Tyrosine Kinase Inhibitor (TKI). Acabrunat 100mg capsule works by inhibiting Bruton’s tyrosine kinase (BTK), a protein that plays role in growth and survival of malignant B cells. By blocking the protein, the medicine helps to slow down or stop progression of cancer cells in the body.

Mantle cell lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia

Medications show side effects as they act on multiple pathways in the body, just like that Acabrunat 100mg capsule may also cause certain side effects because it affects not only cancerous B cells but can also influence normal cells involved in immune and blood functions. Some of them are:
● Anaemia
● Low blood platelets
● Headache
● Diarrhea
● Decreased white blood cell count
● Upper respiratory tract infections
● Musculoskeletal pain

The capsule can be taken orally, twice a day usually with or without food exactly as prescribed by the healthcare provider to ensure proper absorption and effectiveness. Do not skip the medication, and if a dose is missed, try to take it as soon unless it’s time for the next dose but never double up the dose to make up for the missed one.

Acabrunat 100mg capsule works by inhibiting Bruton’s tyrosine kinase (BTK), it disrupts the signaling pathways that cancerous B cells use to survive, this slow down or stops the growth and spread of cancer cells. This improves the function of immune system to fight against abnormal cells more effectively and helping to control the progression of the disease.

• Yadav, B. A., & Kuchana, V. (2024). Analytical method development and validation for the estimation of acalabrutinib in API form and marketed pharmaceutical dosage form by RP-HPLC along with stability studies.
• Wu, J., Zhang, M., & Liu, D. (2016). Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. Journal of hematology & oncology, 9(1), 21.
• Markham, A., & Dhillon, S. (2018). Acalabrutinib: first global approval. Drugs, 78(1), 139-145.
• Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., ... & Furman, R. R. (2016). Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 374(4), 323-332.
• Brown, J. R., Seymour, J. F., Jurczak, W., Aw, A., Wach, M., Illes, A., ... & Ghia, P. (2025). Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. New England Journal of Medicine, 392(8), 748-762.